Scholar Rock develops antibody medicines that target myostatin for spinal muscular atrophy and other rare neuromuscular diseases. It last closed at $45.11 on Nov 17, up 1.28% on the day. SRRK last reported earnings on Tue, Nov 10, 2026. The average 12-month price target from 11 analysts is $71.55 (+58.6% from the last close), with a high of $84.00 and a low of $58.00. Analyst consensus is Strong Buy, based on the latest ratings from 11 firms (10 buy, 1 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $2.3M, the largest $2.3M.
Each firm's latest rating on SRRK in the past 90 days
Average 12-month target
$71.55
▲ 58.6% upside
Based on 11 analysts who set a price target on SRRK in the past 90 days. The average target is $71.55, with a high of $84.00 and a low of $58.00, compared with the last close of $45.11.
Low $58.00Avg $71.55High $84.00
Blue marker: last close $45.11
Highest target$84.00
Average target$71.55
Lowest target$58.00
Latest rating changes
Truist SecuritiesTarget raised
Sep 24Buy$76 → $77
JP MorganTarget raised
Sep 21Buy$63 → $70
Evercore ISI GroupMaintained
Sep 15Buy$72
Piper SandlerTarget raised
Sep 15Buy$42 → $75
JefferiesMaintained
Sep 15Buy$65
Date
Firm
Action
Rating
Price target
Sep 24
Truist Securities
Target raised
Buy
$76 → $77
Sep 21
JP Morgan
Target raised
Buy
$63 → $70
Sep 15
Evercore ISI Group
Maintained
Buy
$72
Sep 15
Piper Sandler
Target raised
Buy
$42 → $75
Sep 15
Jefferies
Maintained
Buy
$65
Loading…
Technical Analysis
SRRK · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend
The stock sits between its 20 and 50 day averages. It is 7% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 50). The nearest support is the Pivot at $44.52, and the nearest resistance the swing high (Oct 29) at $45.19.
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 5.3%/day
Key levels
$61.7652 week high+36.9%
$49.58100 day average+9.9%
$48.23200 day average+6.9%
$45.77Pivot R1+1.5%
$45.6750 day average+1.2%
$45.19Swing high (Oct 29)+0.2%
$45.11Last close
$44.52Pivot−1.3%
$44.4820 day average−1.4%
$43.87Pivot S1−2.7%
$43.23Swing low (Jun 11)−4.2%
$35.5352 week low−21.2%
Indicators
RSI (14)
50.43
Middle of its range
Neutral
MACD
0.12
Above its signal line
Bullish
Stochastic
22.4
Middle of its range
Neutral
ADX (14)
24.1
Weak trend
Williams %R
-74.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
4.3
Oversold below −100, overbought above 100
Neutral
Rate of change
+2.6%
Change over 10 sessions
Bullish
ATR (14)
$2.40
Typical daily range, 5.3% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumFading
StretchNormal
VolatilityNormal, 11.5%/day
Key levels
$61.7652 week high+36.9%
$49.58100 day average+9.9%
$48.23200 day average+6.9%
$45.77Pivot R1+1.5%
$45.6750 day average+1.2%
$45.19Swing high (Oct 29)+0.2%
$45.11Last close
$44.52Pivot−1.3%
$44.4820 day average−1.4%
$43.87Pivot S1−2.7%
$43.23Swing low (Jun 11)−4.2%
$35.5352 week low−21.2%
Indicators
RSI (14)
47.08
Middle of its range
Neutral
MACD
-1.23
Below its signal line
Bearish
Stochastic
27.7
Middle of its range
Neutral
ADX (14)
16.4
No clear trend
Williams %R
-72.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
-73.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−18.6%
Change over 10 sessions
Bearish
ATR (14)
$5.19
Typical daily range, 11.5% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Above
MA 200–
What happened before, for SRRK
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how SRRK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow SRRK usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How SRRK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SRRK is in one of them and how their past SRRK trades turned out.
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts. It develops antibody medicines for people with spinal muscular atrophy (SMA) and other rare, severe neuromuscular diseases. Its lead product candidate, apitegromab, blocks myostatin, a protein that limits muscle growth, and is being studied in SMA and facioscapulohumeral muscular dystrophy. The company is also developing a subcutaneous form of apitegromab and is seeking regulatory approval in the United States and Europe.